Similar articles

• Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.

  Thompson IM, Zeidman EJ, Rodriguez FR. Thompson IM, et al. J Urol. 1990 Dec;144(6):1479-80. doi: 10.1016/s0022-5347(17)39774-4. J Urol. 1990. PMID: 2122011 Review.
• A comparison of a powerful luteinizing hormone releasing hormone analogue agonist and estrogen in the treatment of advanced prostatic cancer.

  Winfield H, Trachtenberg J. Winfield H, et al. J Urol. 1984 Jun;131(6):1107-9. doi: 10.1016/s0022-5347(17)50832-0. J Urol. 1984. PMID: 6427477 Clinical Trial.
• [Study on prevention of flare-up phenomenon following initial LH-RH analogue administration: combination therapy with diethylstilbestrol].

  Takeuchi S, Yoshida K, Tosaka A, Kobayashi N, Higashi Y, Negishi T. Takeuchi S, et al. Hinyokika Kiyo. 1995 Mar;41(3):191-6. Hinyokika Kiyo. 1995. PMID: 7741071 Clinical Trial. Japanese.
• Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of prostate.

  Sharifi R, Lee M, Ojeda L, Ray P, Stobnicki M, Guinan P. Sharifi R, et al. Urology. 1985 Aug;26(2):117-24. doi: 10.1016/0090-4295(85)90042-1. Urology. 1985. PMID: 3927551 Clinical Trial.
• [The effective therapy of the hot flashes during hormone withdrawal treatment in patients with advanced prostatic carcinoma].

  Kliesch S, Behre HM, Roth S. Kliesch S, et al. Dtsch Med Wochenschr. 1997 Jul 25;122(30):940-5. doi: 10.1055/s-2008-1047713. Dtsch Med Wochenschr. 1997. PMID: 9280708 Review. German. No abstract available.